Resources

This circular is to advise stakeholders of the publication of a high level summary and individual submissions.

The document contains advice on the third and final reduction of benefits for Cardiac Implantable Electronic Devices (CIED) effective 1 July 2025.

This page lists the medical devices and human tissue products private health insurers must pay benefits for to the patients who have appropriate insurance policies. The latest version of the Prescribed List is effective from 1 July 2025.

This document provides a high-level summary of stakeholder feedback received in response to Consultation Paper 9 – CIED and the cost of technical support services.

We have developed a Prescribed List Post-listing Review Framework that is used to guide the post-listing review process as part of the Prescribed List Reforms.

The interim evaluation report covers the period from May 2021 to June 2024 and reports on whether the reforms being implemented and achieving the expected outcomes.

This report is to provide an analysis of stakeholder feedback received.

We established an Implementation Advisory Group to develop a roadmap for sequencing the government’s response to the recommendations. This document contains MSAC chair's response to the Minister regarding the final report of the HTA Review and provided their initial advice and reflections.

We established an Implementation Advisory Group to develop a roadmap for sequencing the government’s response to the recommendations. This document contains PBAC chair's response to the Minister regarding the final report of the HTA Review and provided their initial advice and reflections.

This evaluation focuses on the Prostheses List reforms, which are running from 1 July 2021 to 30 June 2025. Evaluation of these reforms will determine whether the reform program is being implemented as intended.

This list includes details of the 26 billing codes for medicines and related accessories scheduled to be removed from Part D of the Prescribed List effective 1 November 2024.

This report provides an analysis of stakeholder feedback received in response to the Consultation Paper on the proposed Compliance, Assurance and Information sharing measures for the Prescribed List (PL).

This report provides an analysis of stakeholder feedback received in response to the consultation paper on the proposed measure: Prescribed List (PL) gifts, benefits and discounts reporting requirements.

This report provides an analysis of stakeholder feedback received in response to the consultation paper on the proposed measure: alignment of amount charged for supply of a device with corresponding PL benefit.

The Enhanced Consumer Engagement Process was developed to provide recommendations on how to increase patient and consumer evidence and input earlier in the Health Technology Assessment (HTA) process. This report explains the recommendations developed by the Co-Design Working Group.

This document is the final report from the Health Technology Assessment Policy and Methods Review.

This document summarises the recommendations from the Health Technology Assessment Policy and Methods Review report.

This document outlines all of the recommendations from the Health Technology Assessment Policy and Methods Review final report.

This report is a review of surgical guides and biomodels currently listed on the Prostheses List.

These documents contain advice on the Prescribed List (PL) adjusted benefits, resulting from the public benchmarking undertaken by the Independent Health and Aged Care Pricing Authority (IHACPA). The documents outline the November 2023 PL benefits, and the adjusted benefits effective 1 July 2024.

This consultation document describes the proposed recommendations for the co-design of an Enhanced Consumer Engagement Process related to health technology assessment (HTA). Read this first to inform your responses to the consultation.